Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer - PubMed
5 hours ago
- #CDK4/6 inhibitors
- #retreatment
- #metastatic breast cancer
- CDK4/6 inhibitors combined with endocrine therapy are first-line treatment for HR+/HER2- metastatic breast cancer.
- Retrospective study of 78 patients evaluated retreatment with different CDK4/6 inhibitor sequences after prior exposure.
- Palbociclib after abemaciclib showed the most favorable outcomes with a median time to treatment failure of 10 months.
- 64.5% of patients on palbociclib retrial after abemaciclib had longer treatment failure times than initial therapy.
- Discontinuation due to adverse events trended toward longer retrial benefit compared to progression-driven discontinuation.
- Visceral metastasis predicted poorer retreatment outcomes, especially in the palbociclib-after-abemaciclib cohort.
- Study supports individualized patient selection for CDK4/6 inhibitor retrial, warranting prospective validation.